Good

FRO – Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, February 29, 2024

FRONTLINE PLC REPORTS RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2023

Key Points: 
  • FRONTLINE PLC REPORTS RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2023
    Frontline plc (the “Company” or “Frontline”), today reported unaudited results for the three and twelve months ended December 31, 2023:
    Profit of $118.4 million, or $0.53 per share for the fourth quarter of 2023.
  • Adjusted profit of $102.2 million, or $0.46 per share for the fourth quarter of 2023.
  • Declared a cash dividend of $0.37 per share for the fourth quarter of 2023.
  • Reported revenues of $415.0 million for the fourth quarter of 2023.

Good Supply Launches New ‘Juiced’ Cannabis Pre-Roll Multi-Packs Across Canada

Retrieved on: 
Tuesday, February 27, 2024

Good Supply’s new infused GOOD SUPPLY JUICED™ lineup includes its first duo blunt multi-pack with the new 2x1g ‘Cherry on Top’ Blunts and a refreshed rotation of flavours in its new multi-strain 3x0.5g Discovery Pack.

Key Points: 
  • Good Supply’s new infused GOOD SUPPLY JUICED™ lineup includes its first duo blunt multi-pack with the new 2x1g ‘Cherry on Top’ Blunts and a refreshed rotation of flavours in its new multi-strain 3x0.5g Discovery Pack.
  • First making its appearance across retailers last summer , Good Supply’s fruit-forward ‘JUICED’ infused pre-roll collection continues to expand with bold and fruity flavours drawing from Good Supply’s acclaimed fan-favourite offerings.
  • Good Supply’s single-flavour pre-roll multi-packs, multi-flavour discovery pre-roll pack, and indulgent blunts feature a pairing of strain-specific flower with the fruit-flavoured extract of Good Supply’s best-selling vapes.
  • The latest additions to the Good Supply JUICED lineup include:
    For its first drop, Good Supply launched its Groovy Grape and Bunches of Bananas Juiced Infused single 1g Blunts.

Semilux International Ltd. Announces Closing of up to $50 Million Common Stock Purchase Transaction with White Lion Capital

Retrieved on: 
Thursday, February 22, 2024

Taipei, Taiwan, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Semilux International Ltd. ("Semilux" or the "Company") (NASDAQ: SELX), a provider of application-specific integrated circuit (“ASIC”), LiDAR and ADB components and solutions, today announced that it has entered into a common stock purchase agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"), a Nevada limited liability company.

Key Points: 
  • Taipei, Taiwan, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Semilux International Ltd. ("Semilux" or the "Company") (NASDAQ: SELX), a provider of application-specific integrated circuit (“ASIC”), LiDAR and ADB components and solutions, today announced that it has entered into a common stock purchase agreement (the "Agreement") with White Lion Capital, LLC ("White Lion Capital"), a Nevada limited liability company.
  • The Agreement governs a committed equity facility that provides the Company with the right, without the obligation, to sell White Lion Capital up to $50 million of its common stock, subject to certain limitations and conditions.
  • The Company intends to use the net proceeds from the transaction for working capital to advance the Company’s ASIC, LiDAR, and ADB technologies to meet the industry's growing demand for safety standards.
  • Dr. Yung-Peng Chang, Chairman of the Board, Director and Co-Chief Executive Officer of Semilux, commented, "We are pleased to announce the closing of the Agreement with White Lion Capital.

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

Retrieved on: 
Thursday, February 22, 2024

Sodexo and AstraZeneca extend their global partnership for a further 5 years.

Key Points: 
  • Sodexo and AstraZeneca extend their global partnership for a further 5 years.
  • Sodexo and AstraZeneca have built a trusting relationship over the years, with significant advances implemented to improve the daily lives of consumers.
  • The collaboration between Sodexo and AstraZeneca began in 2008 in the UK with a first Food and Facilities Management contract.
  • Johan Stellingwerf, Sodexo Chief Operating Officer for Global Strategic Accounts said: “We are very pleased to have extended our long-lasting partnership with AstraZeneca.

AM Best Removes From Under Review With Positive Implications and Upgrades Credit Ratings of Triple-S Propiedad, Inc.

Retrieved on: 
Friday, March 8, 2024

The outlook assigned to these Credit Ratings (ratings) is stable.

Key Points: 
  • The outlook assigned to these Credit Ratings (ratings) is stable.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .
  • AM Best is a global credit rating agency, news publisher and data analytics provider specializing in the insurance industry.

AM Best Assigns Credit Ratings to Lone Peak Insurance Company

Retrieved on: 
Thursday, March 7, 2024

AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating of “bbb+” (Good) to Lone Peak Insurance Company (Lone Peak) (South Jordan, Utah).

Key Points: 
  • AM Best has assigned a Financial Strength Rating of B++ (Good) and a Long-Term Issuer Credit Rating of “bbb+” (Good) to Lone Peak Insurance Company (Lone Peak) (South Jordan, Utah).
  • Lone Peak was formed in 2019 in Utah, and writes, both on an assumed and direct basis, failure to perform contractual liability insurance policies (CLIPs).
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

AM Best Affirms Credit Ratings of Halyk Insurance Company JSC

Retrieved on: 
Thursday, March 7, 2024

AM Best has affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb” (Good) of the Joint-Stock Company Subsidiary of Halyk Bank of Kazakhstan Halyk Insurance Company (Halyk Insurance) (Kazakhstan).

Key Points: 
  • AM Best has affirmed the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of “bbb” (Good) of the Joint-Stock Company Subsidiary of Halyk Bank of Kazakhstan Halyk Insurance Company (Halyk Insurance) (Kazakhstan).
  • AM Best does not consider Halyk Insurance’s financial strength to be affected by the weaker credit profile of its parent, Halyk Savings Bank of Kazakhstan JSC.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

AM Best Removes From Under Review With Negative Implications and Affirms Credit Ratings of WT Holdings, Inc. and Subsidiary

Retrieved on: 
Thursday, March 7, 2024

Concurrently, AM Best has removed from under review with negative implications and affirmed the Long-Term ICR of “bbb-­” (Good) of WT Holdings, Inc. (Memphis, TN).

Key Points: 
  • Concurrently, AM Best has removed from under review with negative implications and affirmed the Long-Term ICR of “bbb-­” (Good) of WT Holdings, Inc. (Memphis, TN).
  • The outlook assigned to these Credit Ratings (ratings) is negative.
  • The ratings reflect Stillwater’s balance sheet strength, which AM Best assesses as strong, as well as its adequate operating performance, neutral business profile and appropriate enterprise risk management.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .

AM Best Affirms Credit Ratings of Atlantic American Corporation and Its Subsidiaries

Retrieved on: 
Wednesday, March 6, 2024

Concurrently, AM Best has affirmed the Long-Term ICR of “bbb-” (Good) of the parent company, Atlantic American Corporation (Atlantic American) [NASDAQ: AAME].

Key Points: 
  • Concurrently, AM Best has affirmed the Long-Term ICR of “bbb-” (Good) of the parent company, Atlantic American Corporation (Atlantic American) [NASDAQ: AAME].
  • Financial flexibility is sufficient considering the group’s strongest BCAR scores and access to capital markets through the publicly traded parent company, Atlantic American.
  • For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best's Credit Ratings .
  • For information on the proper use of Best’s Credit Ratings, Best’s Performance Assessments, Best’s Preliminary Credit Assessments and AM Best press releases, please view Guide to Proper Use of Best’s Ratings & Assessments .

Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer

Retrieved on: 
Tuesday, March 5, 2024

Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate.

Key Points: 
  • Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate.
  • Current research and monitoring indicate that this is the first time GMP manufacturing of a therapeutic IgE antibody has been completed at scale.
  • Epsilogen intends to use this new material for its upcoming Phase Ib study in platinum-resistant ovarian cancer (PROC) patients, scheduled to start later in 2024.
  • Lonza and Epsilogen have worked together to apply Lonza’s knowledge and experience to MOv18 IgE.